Results 111 to 120 of about 8,545 (210)

Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease [PDF]

Purpose Besides the well-established efficacy in preventing severe COVID-19, the impact of early treatments, namely antivirals and monoclonal antibodies (mAbs), on the time length to negativization of SARS-CoV-2 nasal swabs is still unclear.
Antinori, Spinello, Bergna, Annalisa, Bernasconi, Davide, Borghetti, Silvia, Casalini, Giacomo, Colaneri, Marta, Colombo, Valeria, Corbellino, Mario, Cordier, Laura, Dedivitiis, Gianfranco, Fassio, Federico, Gabrieli, Arianna, Galli, Lucia, Gori, Andrea, Lai, Alessia, Riva, Agostino, Rizzardini, Giuliano, Scaglione, Giovanni, Schiavini, Monica, Sollima, Salvatore, Tarkowski, Maciej, Ventura, Carla Della, Visigalli, Debora   +22 more
core   +1 more source

Comprehensive genotoxicity and carcinogenicity assessment of molnupiravir

Toxicological Sciences
Abstract Molnupiravir is registered or authorized in several countries as a 5-d oral coronavirus disease 2019 treatment for adults. Molnupiravir is a prodrug of the antiviral ribonucleoside β-D-N4-hydroxycytidine (NHC) that distributes into cells, where it is phosphorylated to its pharmacologically active ribonucleoside triphosphate (NHC-
Patricia A Escobar, Zhanna Sobol, Randy R Miller, Sandrine Ferry-Martin, Angela Stermer, Binod Jacob, Nagaraja Muniappa, Rosa I Sanchez, Kerry T Blanchard, Alema Galijatovic-Idrizbegovic, Rupesh P Amin, Sean P Troth   +11 more
openaire   +2 more sources

Cost-effectiveness Analysis of Nirmatrelvir/Ritonavir Compared with Molnupiravir in Patients at High Risk for Progression to Severe COVID-19 in Japan

Journal of Health Economics and Outcomes Research
# Background Nirmatrelvir/ritonavir (NMV/r) and molnupiravir are oral antiviral drugs approved for the treatment of early symptomatic patients with mild to moderate COVID-19 at high risk of progression to severe disease in Japan.
Akira Yuasa, Hiroyuki Matsuda, Yosuke Fujii, Tendai Mugwagwa, Yuki Kado, Mizuki Yoshida, Koichi Murata, Yoshiaki Gu   +7 more
doaj   +1 more source

Effect of Nucleic Acid Analog Administration on Fluctuations in the Albumin-to-Globulin Ratio in Cats with Feline Infectious Peritonitis

Animals
Background: feline infectious peritonitis (FIP) is a fatal disease in cats classified as either effusive (‘wet’), non-effusive (‘dry’), or a mixture of both forms (‘mixed’).
Masato Katayama, Yukina Uemura, Daichi Katori   +2 more
doaj   +1 more source

Full factorial design assisted RP-UHPLC method development and study of stressed degradation of molnupiravir [PDF]

To combat the SARS-CoV-2 addition of molnupiravir into the current therapeutic regimen has added new hopes. But currently, not so many analytical methods are available for analyzing molnupiravir.
Faruk, Omar, Kumar, Uttom, Lira, Dilshad Noor, Rouf, Abu Shara Shamsur, Shill, Diponkor Kumar   +4 more
core   +1 more source

Garlic peel-based carbon quantum dots as a sustainable alternative for the sensitive and green spectrofluorometric quantification of molnupiravir in pharmaceutical capsules

Heliyon
Searching for natural alternatives to replace environmentally harmful chemical reagents in analysis is just as crucial as finding easily accessible analytical tools.
Yomna A. Saber, Mahmoud Hamed, Samy Emara, Fotouh R. Mansour, Marcello Locatelli, Noha Ibrahim   +5 more
doaj   +1 more source

The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronaviruses [PDF]

Despite the wide availability of several safe and effective vaccines that prevent severe COVID-19, the persistent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) that can evade vaccine-elicited ...
Adams, Lily E, Babusis, Darius, Bannister, Roy, Baric, Ralph S, Baric, Thomas J, Barrett, Kimberly T, Bilello, John P, Brown, Ariane J, Catanzaro, Nicholas J, Cihlar, Tomas, Conrad, Helen, De la Cruz, Gabriela, Diefenbacher, Meghan V, Dong, Stephanie, Feng, Joy Y, Gully, Kendra L, Kalla, Rao, Mackman, Richard L, Mallory, Michael L, Martinez, David R, May, Samantha R, Montgomery, Stephanie A, Moreira, Fernando R, Nguyen, Anh-Hoa, Nguyen, Anh-Quan, Nguyen, Cameron, Perry, Jason K, Schäfer, Alexandra, Scobey, D Trevor, Sheahan, Timothy P, Yount, Boyd, Zweigart, Mark R   +31 more
core   +2 more sources

Synthesis of Molnupiravir [PDF]

Synfacts, 2022
openaire   +1 more source

A Phase 2a, Randomized, Placebo-Controlled Human Challenge Trial to Evaluate the Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated with Respiratory Syncytial Virus

Pulmonary Therapy
Introduction Human respiratory syncytial virus (RSV) infections can result in hospitalization and/or death among vulnerable populations. Molnupiravir is a prodrug of ß-D-N4-hydroxycytidine, which has broad-spectrum preclinical activity against RNA ...
Mickie H. Cheng, Alex J. Mann, Brian M. Maas, Tian Zhao, Melissa Bevan, Andrea K. Schaeffer, Laura E. Liao, Andrew P. Catchpole, David W. Hilbert, S. Aubrey Stoch, Carisa S. De Anda   +10 more
doaj   +1 more source

Clinical Outcome and 7-Day Virological Clearance in High-Risk Patients with Mild–Moderate COVID-19 Treated with Molnupiravir, Nirmatrelvir/Ritonavir, or Remdesivir [PDF]

Introduction: We compared the effectiveness and virological clearance (VC) at day 7 (T7) post-treatment with molnupiravir, nirmatrelvir/ritonavir, and remdesivir in SARS-CoV-2-infected patients at high risk (HR) for clinical progression. Methods: We
Albertini, Lorenzo, Augello, Matteo, Bai, Francesca, Beringheli, Tomaso, Biasioli, Lorenzo, Bini, Teresa, Bono, Valeria, Castoldi, Roberto, Copes, Alessandro, Gemignani, Nicole, Ligresti, Riccardo, Lundgren, Lorenzo Brando, Marchetti, Giulia, Molà, Francesco, Monforte, Antonella d'Arminio, Nardo, Riccardo, Orfeo, Nicola Vincenzo, Passarella, Sabrina, Pettenuzzo, Sofia, Rovito, Roberta, Sala, Matteo, Santoro, Andrea, Varisco, Benedetta, Vitaletti, Virginia   +23 more
core   +1 more source